Sun Pharma's $11.75 billion Organon deal: India's biggest pharma acquisition
Synopsis
Sun Pharma's $11.75 billion all-cash bid for Organon is not just India's largest pharma acquisition — it's a strategic leap into biosimilars and women's health that could vault the Mumbai-based drugmaker into the global top 25. With $12.4 billion in combined revenues on the table, this deal rewrites the scale of Indian pharma's global ambitions.
Key Takeaways
Sun Pharmaceutical Industries announced the acquisition of Organon & Co on 27 April in an all-cash deal valued at $11.75 billion — India's largest-ever pharma overseas acquisition.
The deal values Organon shares at $14 per share , with an equity value of approximately $3.99 billion .
The combined entity is projected to generate revenues of $12.4 billion , placing it among the top 25 global pharmaceutical companies .
Organon reported revenue of $6.2 billion and adjusted EBITDA of $1.9 billion for the year ended December 2025 .
The transaction is expected to close in early 2027 , pending regulatory and shareholder approvals.
Sun Pharma shares surged 6.71% to an intraday high of ₹1,728.65 on the BSE following the announcement.
Sun Pharmaceutical Industries on Monday, 27 April announced it will acquire New York-listed Organon & Co in an all-cash deal valued at $11.75 billion, marking the largest overseas acquisition ever undertaken by an Indian pharmaceutical company. The announcement sent Sun Pharma shares surging as much as 6.71% to an intraday high of ₹1,728.65 on the BSE.
Deal Structure and Valuation
Under the agreement, Sun Pharma will acquire 100% of Organon's outstanding shares at $14 per share, translating into an enterprise valuation of $11.75 billion and an equity value of approximately $3.99 billion. The transaction has been approved by the boards of both companies and is expected to close in early 2027, subject to regulatory approvals and Organon shareholder consent. Sun Pharma plans to fund the deal through a combination of internal accruals and debt financing.
What Sun Pharma Gets
New Jersey-based Organon operates across three core segments: women's health, biosimilars, and established medicines. The company carries a portfolio of over 70 products and a commercial presence in more than 140 countries. For the year ended December 2025, Organon reported revenue of $6.2 billion and adjusted EBITDA of $1.9 billion. The acquisition will allow Sun Pharma to enter the biosimilars segment as a top-tier global player — a space it has so far had limited exposure to.
Strategic Rationale
The combined entity is expected to rank among the top 25 global pharmaceutical companies, with projected revenues of approximately $12.4 billion. Sun Pharma said the deal aligns with its strategy to scale its innovative medicines business while reinforcing its position in established brands and branded generics. Notably, the acquisition also deepens Sun Pharma's footprint in women's health — a segment where Organon holds a globally recognised portfolio.
What the Leadership Said
Sun Pharma Executive Chairman Dilip Shanghvi said the acquisition would help build a stronger and more diversified platform. Managing Director Kirti Ganorkar highlighted synergy and growth opportunities expected from the integration of the two companies' operations and product lines.
Market Reaction and What's Next
Sun Pharma shares responded sharply to the announcement, rising as much as 6.71% to hit an intraday high of ₹1,728.65 on the BSE in early Monday trade. Regulatory clearances across multiple jurisdictions — given Organon's presence in over 140 countries — will be a key milestone before the deal can close. The transaction, if completed as planned, will fundamentally reshape Sun Pharma's global scale and competitive positioning in the pharmaceutical landscape.
Point of View
Sun Pharma leapfrogs years of organic build-up in a segment that is rapidly becoming the next frontier of global pharma competition. The deal's real test, however, will be integration: Organon operates across 140 countries with a complex multi-segment portfolio, and the debt financing component adds execution risk if synergies materialise slower than projected. Indian pharma has long been strong on generics but has struggled to build credible biosimilar or innovative medicine platforms at global scale. If Sun Pharma pulls this off, it sets a new benchmark — and a new pressure — for every other large Indian drugmaker watching from the sidelines.
NationPress
1 May 2026
Frequently Asked Questions
What is the Sun Pharma and Organon deal?
Sun Pharmaceutical Industries has announced an all-cash acquisition of New York-listed Organon & Co for $11.75 billion, making it the largest overseas acquisition by an Indian pharmaceutical company. The deal values Organon shares at $14 per share, with an equity value of approximately $3.99 billion.
When is the Sun Pharma-Organon deal expected to close?
The transaction is expected to close in early 2027, subject to regulatory approvals across multiple jurisdictions and approval from Organon's shareholders. Both companies' boards have already approved the deal.
How will Sun Pharma fund the Organon acquisition?
Sun Pharma plans to fund the $11.75 billion deal through a combination of internal accruals and debt financing. The exact debt-to-accrual split has not been publicly detailed.
What does Organon bring to Sun Pharma?
Organon operates in women's health, biosimilars, and established medicines, with over 70 products and a presence in more than 140 countries. For the year ended December 2025, it reported $6.2 billion in revenue and $1.9 billion in adjusted EBITDA, giving Sun Pharma immediate global scale in biosimilars.
How did Sun Pharma shares react to the Organon deal announcement?
Sun Pharma shares rose as much as 6.71% to hit an intraday high of ₹1,728.65 on the BSE in early trade on Monday, 27 April, reflecting strong initial market approval of the deal.
